Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Performance growth was driven by a combination of new customer acquisition in the Western U.S., increased volume from existing accounts, and disciplined pricing actions.
Management attributed gross margin expansion to 18% to improved operating efficiency and the activation of two new automated liquid production lines. The company is deliberately reducing customer concentration by shifting toward longer-term agreements with annual pricing provisions to increase revenue predictability. Strategic expansion into the Western U.S. aims to challenge the regional monopoly of a single provider by leveraging existing manufacturing and distribution infrastructure.
Operational improvements are focused on creating structural advantages, such as reduced labor intensity and lower production costs, rather than short-term gains. The recent reverse stock split was framed as a strategic move to regain Nasdaq compliance and attract institutional investors, rather than a response to financial distress. Management reiterated its goal of achieving approximately 30% gross margins and over $100 million in annual net sales by 2029.
Future margin expansion is contingent on higher production volumes, increased asset utilization, and continued automation across the manufacturing footprint. The company is evaluating a new medical device opportunity intended to complement the existing renal care platform and leverage current commercial relationships. Full-year 2026 guidance assumes continued momentum in the Western U.S. and the realization of benefits from recent manufacturing investments.
Strategic growth pillars include geographic expansion, broadening the renal care product portfolio, and evaluating innovations to improve the patient experience. The company incurred modest expenses for the development of a new medical device, which management emphasized is being funded entirely through existing cash flow. Management explicitly stated that the reverse stock split will not be followed by a capital raise, distinguishing it from the company's historical actions.
The second quarter marked a return to positive operating cash flow of $2.1 million, which includes the impact of final payments for the Evoqua acquisition. Nvidia-level potential. 30M+ investors trust Moby to find it first. Management noted that Rockwell is now a consistent supplier in the West, providing an alternative to the region's previously sole provider.
Extract — continue reading at the source.
